Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines

Viral Immunology

Volumn 23, Issue 5, 2010, Pages 467-476

  Wu, Shuang ^a   Kanda, Tatsuo ^a   Imazeki, Fumio ^a   Arai, Makoto ^a   Yonemitsu, Yutaka ^a   Nakamoto, Shingo ^a   Fujiwara, Keiichi ^a   Fukai, Kenichi ^a   Nomura, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA INTERFERON; HEPATITIS E ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INHIBITION KINETICS; PROMOTER REGION; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION;

CELL LINE; CYTOKINES; GENE EXPRESSION PROFILING; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; VIRULENCE FACTORS;

HEPATITIS B VIRUS;

EID: 77957743340     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0042     Document Type: Article

References (47)

1. Bellecave P, Gouttenoire J, Gajer M, et al.: Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009;50:46-55.
2. Chang MH, You SL, Chen CJ, et al. and the Taiwan Hepatoma Study Group: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-1355.
3. Chen M, Sallberg M, Hughes J, et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-3027.
4. Chen MT, Billaud JN, Sallberg M, et al.: A function of hepatitis B virus precore proteins to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004;101:14913-14918.
5. Chin R, Earnest-Silveria L, Koeberlein B, et al.: Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatol 2007;47:325-337.
6. Di Bisceglie AM: Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49(5 Suppl): S56-S60.
7. Ehata T, Yokosuka O, Imazeki F, and Omata M: Point mutation in precore region of hepatitis B virus: sequential changes from 'wild' to 'mutant'. J Gastroenterol Hepatol 1996;11:566-574.
8. Eickhoff J, Hanke M, Stein-Gerlach M, et al.: RICK activates a NF-kappaB-dependent anti-human cytomegalovirus response. J Biol Chem 2004;279:9642-9652.
9. Eyre NS, Phillips RJ, Bowden S, et al.: Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009;51:446-457.
10. Fujiwara K, Yokosuka O, Ehata T, et al.: The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. Dig Dis Sci 1998;43:368-376.
11. Hiraga N, Imamura M, Hatakeyama T, et al.: Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol 2009;51:1046-1054.
12. Ito K, Kim KH, Lok A S F, and Tong S: Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009;83:3507-3517.
13. Kanda T, Yokosuka O, Kato N, et al.: Hepatitis A virus VP3 may activate serum response element associated transcription. Scand J Gastroenterol 2003;38:307-313.
14. Kanda T, Yokosuka O, Imazeki F, et al.: Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004;11:479-487.
15. Kanda T, Yokosuka O, Imazeki F, Arai M, and Saisho H: Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol 2005;24:805-809.
16. Kanda T, Steele R, Ray R, and Ray RB: Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol 2007;81:12375-12381.
17. Kanda T, Steele R, Ray R, and Ray RB: Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice. J Virol 2009;83:8463-8469.
18. Kawai T, and Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008;1143:1-20.
19. Kekule AS, Lauer U, Weiss L, Luber B, and Hofschneider PH: Hepatitis B virus transactivator HBx uses a tumor promoter signaling pathway. Nature 1993;361:742-745.
20. Koziel MJ: Cytokines in viral hepatitis. Semin Liver Dis 1999;19:157-169.
21. Lavanchy D: Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34(Suppl 1): S1-S3.
22. Liu S, Gallo DJ, Green AM, et al.: Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun 2002;70:3433-3442.
23. Locarnini S, Shaw T, Dean J, et al.: Cellular response to conditional expression of hepatitis B virus precore and core proteins in cultured hepatoma (Huh7) cells. J Clin Virol 2005;32:113-121.
24. Liu CJ, Chen PJ, and Chen DS: Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 2009;3:517-525.
25. Lok A S F, and McMahon BJ: Chronic hepatitis B. Hepatology 2007;45:507-539.
26. Messageot F, Salhi S, Eon P, and Rossignol JM: Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003;278:891-895.
27. Milich DR, Chen MK, Hughes JL, and Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapside: a mechanism for persistence. J Immunol 1998;160:2013-2021.
28. Niwa H, Yamamura K, and Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-200.
29. Omata M, Ehata T, Yokosuka O, Hosoda K, and Ohto M: Mutations in the precore region of hepatitis B virus DNA in patients with fulminant hepatitis and severe hepatitis. N Engl J Med 1991;324:1699-1704.
30. Palori M, Carloni G, Alfani E, De Petrillo G, and Barnaba V: Interleukin-6 production by human hepatoma lines is related to a low degree of cell differentiation. Res Virol 1993;144:323-326.
31. Park CY, Oh SH, Kang SM, Lim YS, and Hwang SB: Hepatitis delta virus large antigen sensitizations to TNF-alphainduced NF-kappaB signaling. Mol Cells 2009;28:49-55.
32. Preiss S, Thompson A, Chen X, et al.: Characterization of the innate immune signaling pathways in hepatocyte cell lines. J Viral Hepat 2008;15:888-900.
33. Qin Y, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, and Lahn BT: Systemic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 2010;5: e10611.
34. Raetzsch CF, Brooks NL, Alderman JM, et al.: Lipopolysaccharide inhibition of glucose production through the Tolllike receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology 2009;50:592-600.
35. Ray RB, Steele R, Basu A, Meyer K, Majumder M, Ghosh AK, and Ray R: Distinct functional role of hepatitis C virus core protein on NF-kappaB regulation is linked to genomic variation. Virus Res 2002;87:21-29.
36. Sato K, Ishikawa T, Okumura A, et al.: Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:1627-1632.
37. Shepard CW, Simard EP, Finelli L, Fiore AE, and Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112-125.
38. Standring DN, Ou JH, Masiarz FR, and Rutter WJ: A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc Natl Acad Sci USA 1988;85:8405-8409.
39. Sumpter R Jr, Loo YM, Foy E, et al.: Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2007;79:2689-2699.
40. Szabo G, Catalano D, Bellerose G, and Mandrekar P: Interferon alpha and alcohol augment nuclear regulatory factorkappaB activation in HepG2 cells, and interferon alpha increases pro-inflammatory cytokine production. Alcohol Clin Exp Res 2001;25:1188-1197.
41. Teodoro JG, and Querido E: Regulation of apoptosis by viral gene products. J Virol 1997;71:1739-1746.
42. Tong SP, Diot C, Gripon P, Li J, Vitvitski L, Trepo C, and Guguen-Guillouzo C: In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology 1991;181:733-737.
43. Visvanathan K, Skinner NA, Thompson AJ, et al.: Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007:45; 102-110.
44. Wang Z, Zhang J, Yang H, et al.: Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003:71; 360-366.
45. Xu N, Yao HP, Sun Z, and Chen Z: Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 2008:29; 239-244.
46. Yang CY, Kuo TH, and Ting LP: Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response. J Biol Chem 2006;281:34525-34536.
47. Yuh CH, Chang YL, and Ting LP: Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 1992;66:4073-4084.